Filtered By:
Source: Heart Rhythm
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 406 results found since Jan 2013.
Stroke and Dementia Risk in Patients with and without Atrial Fibrillation and Carotid Arterial Disease
We sought to understand the risks of stroke, transient ischemic attack(TIA), and dementia in patients with and without atrial fibrillation (AF) and carotid arterial disease (CD), or a combination of both, and determine if therapies for each disease may influence risks. 11,572 patients were included and matched into 4 groups of 2,893 by the presence of AF and CD. CD and AF augment risk of stroke/TIA and dementia in the general population and the coexistence of both diseases is additive in risk. Ablation of AF was associated with lower risk, the magnitude of which was greater in those with CD.
Source: Heart Rhythm - July 8, 2019 Category: Cardiology Authors: T. Jared Bunch, Tami L. Bair, Brian G. Crandall, Michael J. Cutler, John D. Day, Kevin G. Graves, Victoria Jacobs, Charles Mallender, Jeffrey S. Osborn, J. Peter Weiss, Heidi T. May Source Type: research
EP News: Clinical
Hohnloser et al (Circulation 2019;139:2315, PMID 30976787) assessed the safety and efficacy of once-daily edoxaban 60 mg (30 mg in patients indicated for dose reduction) vs vitamin K antagonists (VKAs) in patients with atrial fibrillation undergoing catheter ablation in a multinational, multicenter, random ized, open-label, parallel-group trial. Patients were randomized 2:1 to edoxaban vs VKA. The primary end point was the time to first occurrence of all-cause death, stroke, or major bleeding during the period from the end of the ablation procedure to the end of treatment (90 days).
Source: Heart Rhythm - June 24, 2019 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research
The Heart Rhythm Society/American College of Physicians Atrial Fibrillation Screening and Education Initiative
The prevalence of both atrial fibrillation (AF) and stroke is increasing. Stroke is common in AF and can have devastating consequences, especially when AF is unrecognized, and anticoagulation is not initiated.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Lynda E. Rosenfeld, Alpesh Navin Amin, Jonathan C. Hsu, Asa Oxner, Mellanie True Hills, David S. Frankel Source Type: research
Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Due to very high thromboembolic risk, life-long oral anticoagulation is recommended in all hypertrophic cardiomyopathy (HCM) patients with non-valvular atrial fibrillation (NVAF).1-3 We read with great interest the paper by Tsuda et al.4 who rightly emphasized the importance of HCM on thromboembolism in patients with AF.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Source Type: research
Author's reply to Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Dr. Joung and colleagues for their interests in our work.1 In our study, patients with non-valvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than NVAF patients without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study of Jung et al.,2 the stroke risk in NVAF with HCM without any other stroke risk factor was greater than that in NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all NVAF patients with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research
To the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Because of high thromboembolic risk, lifelong oral anticoagulation is recommended in all patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM).1 –3 We read with great interest the article by Tsuda et al,4 who rightly emphasized the importance of HCM in thromboembolism in patients with AF.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Tags: Letter to the Editor Source Type: research
Reply to the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Joung et al for their interest in our work.1 In our study, patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than did patients with NVAF without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study by Jung et al,2 stroke risk in patients with NVAF with HCM without any other stroke risk factor was higher than that in patients with NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all patients with NVAF with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research
Cryoballoon Pulmonary Vein Ablation and Left Atrial Appendage Closure Combined Procedure: a long term follow up analysis Cryoablation with Concomitant Left Atrial Appendage Closure
combined left atrial appendage closure (LAAC) and cryo-energy pulmonary vein isolation (PVI) procedure has been proven safe and effective in managing stroke in patients with non-valvular atrial fibrillation (AF), although most data refer to procedures performed using radiofrequency (RF) as main energy source.
Source: Heart Rhythm - March 26, 2019 Category: Cardiology Authors: Gaetano Fassini, Alessio Gasperetti, Gianpiero Italiano, Stefania Riva, Massimo Moltrasio, Antonio Dello Russo, Michela Casella, Anna Maltagliati, Fabrizio Tundo, Benedetta Majocchi, Luca Arioli, Ghaliah Al-Mohani, Gianluca Pontone, Mauro Pepi, Claudio To Source Type: research
Cryoballoon pulmonary vein ablation and left atrial appendage closure combined procedure: A long-term follow-up analysis
The combined left atrial appendage closure (LAAC) and cryoenergy pulmonary vein isolation (PVI) procedure has been proven safe and effective in managing stroke in patients with nonvalvular atrial fibrillation (AF), although most data refer to procedures performed using radiofrequency as the main energy source.
Source: Heart Rhythm - March 26, 2019 Category: Cardiology Authors: Gaetano Fassini, Alessio Gasperetti, Gianpiero Italiano, Stefania Riva, Massimo Moltrasio, Antonio Dello Russo, Michela Casella, Anna Maltagliati, Fabrizio Tundo, Benedetta Majocchi, Luca Arioli, Ghaliah Al-Mohani, Gianluca Pontone, Mauro Pepi, Claudio To Source Type: research
Atrial Ca2+/calmodulin-dependent protein kinase II: A druggable master switch of atrial fibrillation-associated atrial remodeling?
Atrial fibrillation (AF) is the most common arrhythmia and is associated with increased morbidity and mortality, with heart failure (HF) and thromboembolism including stroke being the major consequences.1 Thus, stroke prevention with oral anticoagulants is crucial, but highly challenging, for AF management in many patients.2,3 Although our understanding of the underlying molecular mechanisms promoting AF increased substantially over the years, contemporary approaches using drugs are only moderately effective and have substantial side effects, including proarrhythmia.
Source: Heart Rhythm - February 5, 2019 Category: Cardiology Authors: Dobromir Dobrev Tags: Editorial Commentary Source Type: research
Left Atrial Appendage Closure Device Implantation in Patients with Atrial Fibrillation and Prior Intracranial Hemorrhage “No Man Left Behind”
Several LAA closure devices have been developed for patients with atrial fibrillation (AF) seeking an alternative to long-term oral anticoagulation (OAC). The PROTECT AF trial was the first multicenter randomized controlled trial (RCT) comparing LAA closure device vs. OAC with Warfarin. Primary safety events were statistically more frequent in the device group (7.4% vs. 4.4%). At a mean follow up of 3.8 years LAA closure device showed superiority for the primary efficacy endpoint (i.e., composite of stroke, cardiovascular death and systemic embolism), with a 34% relative risk reduction in total mortality1-3 However, with t...
Source: Heart Rhythm - January 14, 2019 Category: Cardiology Authors: Luigi Di Biase, Jorge Romero Source Type: research
CHA2DS2-VASc scores and Intermountain Mortality Risk Scores for the joint risk stratification of dementia among patients with atrial fibrillation
High CHA2DS2-VASc scores in atrial fibrillation (AF) patients are generally associated with increased risks of stroke and dementia. At lower CHA2DS2-VASc scores, there remains an unquantifiable cranial injury risk, necessitating an improved risk assessment method within these lower-risk groups.
Source: Heart Rhythm - January 1, 2019 Category: Cardiology Authors: Kevin G. Graves, Heidi T. May, Victoria Jacobs, Kirk U. Knowlton, Joseph B. Muhlestein, Donald L. Lappe, Jeffrey L. Anderson, Benjamin D. Horne, T. Jared Bunch Tags: Featured Article Source Type: research
Refining the prediction of stroke in atrial fibrillation: An elusive endeavor
Atrial fibrillation (AF), the most common sustained arrhythmia, is responsible for>20% of all strokes.1 AF-associated strokes are more severe, causing significantly greater long-term disability, accounting for greater resource utilization, and resulting in significantly higher mortality compared to non-AF strokes.2 –4 Oral anticoagulants (OACs) are the standard of care for the prevention of AF-associated stroke and systemic thromboembolism. To date, OACs are the only therapeutic intervention that has been consistently and definitively shown to improve survival in the AF population.
Source: Heart Rhythm - December 18, 2018 Category: Cardiology Authors: Jason G. Andrade, Laurent Macle Tags: Editorial Commentary Source Type: research
Refining the Prediction of Stroke in Atrial Fibrillation. An elusive endeavor
Atrial fibrillation (AF), the most common sustained arrhythmia, is responsible for>20% of all strokes.1 AF-associated strokes are more severe, causing significantly greater long-term disability, accounting for greater resource utilization, and result in significantly higher mortality when compared to non-AF strokes.2-4 Oral anticoagulants (OACs) are the standard of care for the prevention of AF-associated stroke and systemic thromboembolism. To date OACs are the only therapeutic intervention that has been consistently and definitively shown to improve survival in the AF population.
Source: Heart Rhythm - December 18, 2018 Category: Cardiology Authors: Jason G. Andrade, Laurent Macle Source Type: research
